Current Report Filing (8-k)
October 29 2019 - 5:19PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________
FORM
8-K
__________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
October 29, 2019
__________________
EYENOVIA,
INC.
(Exact name of registrant as specified in
its charter)
__________________
Delaware
(State or other jurisdiction of incorporation)
001-38365
|
|
47-1178401
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
295
Madison Avenue, Suite 2400, New York, New York 10017
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including
area code (917) 289-1117
__________________
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant
to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, $0.0001 Par Value
|
|
EYEN
|
|
Nasdaq Capital Market
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this Chapter).
Emerging growth company x
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
On October 29, 2019, Eyenovia, Inc. (the
“Company”) issued a press release announcing that it is advancing the development of its MicroLine program for
the improvement in near vision in patients with presbyopia towards Phase III development. The Company also is prioritizing
its MicroPine (progressive myopia) and MicroStat (mydriasis) programs while deferring development activities for its
MicroProst (glaucoma and ocular hypertension) and MicroTears (red eye and itch relieve/lubrication) programs. The Company
will host a conference call at 5:00 p.m. ET on October 29, 2019 to discuss its reprioritized pipeline. A copy of the press
release and the slides that the Company will use in connection with the conference call are attached as Exhibits 99.1 and
99.2, respectively, and are incorporated herein by reference.
Item 9.01.
|
Financial Statements and Exhibits.
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
EYENOVIA, INC.
|
|
|
|
|
|
|
Date: October 29, 2019
|
By:
|
/s/ John Gandolfo
|
|
|
Name: John Gandolfo
|
|
|
Title: Chief Financial Officer
|
Eyenovia (NASDAQ:EYEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eyenovia (NASDAQ:EYEN)
Historical Stock Chart
From Apr 2023 to Apr 2024